Amazines Free Article Archive - Friday, October 23, 2020
Read about the most recent changes and happenings at
Log into your account or register as a new author. Start submitting your articles right now!
Search our database for articles.
Subscribe to receive articles emailed straight to your email account. You may choose multiple categories.
View our newest articles submitted by our authors.
View our most top rated articles rated by our visitors.
* Please note that this is NOT the ARTICLE manager
Add a new EZINE, or manage your EZINE submission.
Add fresh, free web content to your site such as newest articles, web tools, and quotes with a single piece of code!
Home What's New? Submit/Manage Articles Latest Posts Top Rated Article Search
Subscriptions Manage Ezines
 Article Archive
 Advertising (133418)
 Advice (161142)
 Affiliate Programs (34751)
 Art and Culture (73737)
 Automotive (145653)
 Blogs (75199)
 Boating (9843)
 Books (17221)
 Buddhism (4128)
 Business (1328954)
 Business News (426365)
 Business Opportunities (366330)
 Camping (10967)
 Career (72752)
 Christianity (15847)
 Collecting (11638)
 Communication (115068)
 Computers (241945)
 Construction (38923)
 Consumer (49684)
 Cooking (17066)
 Copywriting (6637)
 Crafts (18205)
 Cuisine (7543)
 Current Affairs (20417)
 Dating (45881)
 EBooks (19691)
 E-Commerce (48223)
 Education (185288)
 Electronics (83503)
 Email (6407)
 Entertainment (159838)
 Environment (28929)
 Ezine (3039)
 Ezine Publishing (5449)
 Ezine Sites (1550)
 Family & Parenting (110922)
 Fashion & Cosmetics (196423)
 Female Entrepreneurs (11845)
 Feng Shui (131)
 Finance & Investment (310447)
 Fitness (106330)
 Food & Beverages (62911)
 Free Web Resources (7939)
 Gambling (30221)
 Gardening (25144)
 Government (10530)
 Health (629687)
 Hinduism (2206)
 Hobbies (44054)
 Home Business (91574)
 Home Improvement (251119)
 Home Repair (46168)
 Humor (4834)
 Import - Export (5453)
 Insurance (45105)
 Interior Design (29581)
 International Property (3485)
 Internet (191001)
 Internet Marketing (146452)
 Investment (22837)
 Islam (1167)
 Judaism (1356)
 Law (80474)
 Link Popularity (4595)
 Manufacturing (20853)
 Marketing (98966)
 MLM (14136)
 Motivation (18218)
 Music (27011)
 New to the Internet (9495)
 Non-Profit Organizations (4048)
 Online Shopping (129629)
 Organizing (7803)
 Party Ideas (11852)
 Pets (38068)
 Poetry (2234)
 Press Release (12682)
 Public Speaking (5635)
 Publishing (7526)
 Quotes (2407)
 Real Estate (126635)
 Recreation & Leisure (95387)
 Relationships (87666)
 Research (16165)
 Sales (80334)
 Science & Technology (110255)
 Search Engines (23486)
 Self Improvement (153216)
 Seniors (6235)
 Sexuality (35947)
 Small Business (49293)
 Software (83012)
 Spiritual (23474)
 Sports (116093)
 Tax (7659)
 Telecommuting (34066)
 Travel & Tourism (307830)
 UK Property Investment (3121)
 Video Games (13428)
 Web Traffic (11739)
 Website Design (56837)
 Website Promotion (36586)
 World News (1000+)
 Writing (35788)
Author Spotlight

I'm Ellisen, nice to meet you! Obviously you're here because you want to know who I am. Wel...more

A social media marketer from London ...more

I love to research products and write reviews only high-quality useful products. ...more

Writing is my passion, Social media marketing is my love. I have written many articles on various ni...more

My Name is Anish Sah, I am an Internet Marketing and SEO Expert, Social Media Guru and young Entrepr...more

Lapatinib and pazopanib combo not found to improve outcomes forpatients with inflammatory breast ca by e55he swrzsnb

Article Author Biography
Lapatinib and pazopanib combo not found to improve outcomes forpatients with inflammatory breast ca by
Article Posted: 12/14/2013
Article Views: 98
Articles Written: 2033
Word Count: 604
Article Votes: 0
AddThis Social Bookmark Button

Lapatinib and pazopanib combo not found to improve outcomes forpatients with inflammatory breast ca

Business,Business News,Business Opportunities
Inflammatory breast cancer is a very aggressive type of cancer associated with early metastasis and poor survival rates, and theprognosis is even worse for patients with tumors expressing theErbB2 receptor. The ErbB2-inhibiting drug lapatinib can slow thespread of cancer cells in individuals with advanced breast cancerwho have already tried other chemotherapy medications. Treatingthese patients with a combination of drugs has the potential toimprove outcomes compared to treatment with lapatinib alone, but ithas not been clear whether the additional benefits outweigh therisks. Now, researchers from Fox Chase Cancer Center and theirinternational collaborators have presented information at the 2012Annual Meeting of the American Society of Clinical Oncology thatwill give clinicians the information needed to make that call. Massimo Cristofanilli, M.D., F.A.C.P., professor of medicine at FoxChase's department of medical oncology and lead investigator of thestudy, and colleagues, conducted a randomized, prospective phase IIclinical study to test the effectiveness of combination therapyconsisting of lapatinib and pazopanib - a drug already approved totreat advanced kidney cancer that works by inhibiting the growth of new blood vessels, whichcan also contribute to breast cancer progression.

They found thatcombination therapy produces greater toxicity without significantclinical benefits in patients with inflammatory breast cancer, whencompared with lapatinib treatment alone. The multicenter trial consisted of patients with relapsedinflammatory breast cancer who had tumors expressing the ErbB2receptor. In a group of 76 patients, individuals who receivedlapatinib and pazopanib had an overall response rate of 45 percentand median progression-free survival of about 14 weeks, comparedwith 29 percent and about 16 weeks, respectively, in patients whowere treated with lapatinib alone. "But the differences in efficacywere not statistically significant," Cristofanilli says. In addition, side effects such as diarrhea , vomiting and liver dysfunction occurred in patients undergoingcombination therapy, but not in individuals who only tooklapatinib.

As a result, 21 percent of the patients undergoingcombination therapy required dose reductions and 55 percentrequired dose interruptions, compared with only 3 percent and 11percent, respectively, of patients who only took lapatinib. Because of the side effects experienced by the first group ofpatients, Cristofanilli and his team used lower doses of lapatiniband pazopanib in a second group of 87 patients. Combination therapyresulted in an overall response rate of 58 percent and medianprogression-free survival of 16 weeks, compared with 47 percent and16 weeks for lapatinib alone, and 31 percent and about 11 weeks forpazopanib alone. "Once again, the outcomes in patients who receivedcombination therapy were not significantly better than those inpatients who took lapatinib alone," Cristofanilli says.

Moreover, signs of liver dysfunction, diarrhea and fatigue were more common in patients who received combination therapy thanin those who were treated with a single drug, and these sideeffects resulted in more frequent dose reductions and interruptionsin patients undergoing combination therapy. "The results demonstrate that combination therapy consisting oflapatinib and pazopanib increases side effects, but does notsignificantly improve clinical outcomes, when compared withtreatment with lapatinib as a single agent," Cristofanilli says."Based on these findings, I don't recommend that this type ofcombination therapy be used to treat patients with inflammatorybreast cancer, but we were able to confirm that lapatinib is aneffective treatment for women with this disease." To follow up on this research, Cristofanilli will continue to studyhow the growth of new blood vessels contributes to inflammatorybreast cancer. "This particular type of disease requires moreattention," he says. "We need to continue to investigate thebiology of this disease and try to design better therapies forthese patients." Additional References Citations.

The e-commerce company in China offers quality products such as China Ferrosilicon Production Process , GSN Ferro Alloys, and more. For more , please visit Ferro Silicon Barium today!

Related Articles - China Ferrosilicon Production Process, GSN Ferro Alloys,

Email this Article to a Friend!

Receive Articles like this one direct to your email box!
Subscribe for free today!

 Rate This Article  
Completely useless, should be removed from directory.
Minimal useful information.
Decent and informative.
Great article, very informative and helpful.
A 'Must Read'.


Do you Agree or Disagree? Have a Comment? POST IT!

 Reader Opinions 
Submit your comments and they will be posted here.
Make this comment or to the Author only:
*Your email will NOT be posted. This is for administrative purposes only.
Comments: *Your Comments WILL be posted to the AUTHOR ONLY if you select PRIVATE and to this PUBLIC PAGE if you select PUBLIC, so write accordingly.
Please enter the code in the image:

 Author Login 
Register for Author Account


Advertiser Login


   Limited Time $60 Offer!
   90  Days-1.5 Million Views  


Great Paranormal Romance


Demonstrated exceptional leadership in the government and private sector at an executive level. Skil...more

Stevert Mckenzie, Travel Enthusiast. ...more

Steve Bye is currently a fiction writer, who published his first novel, ‘Looking Forward Through The...more

I am not a writer nor am I trying to become a writer. I am an average person with average intelligen...more

At LeadGenerators, we specialise in content-led Online Marketing Strategies for our clients in the t...more

I have been involved in nutrition and weight management for over 12 years and I like to share my kn...more

Jason Ng has a huge passion for the health and fitness industry as he strongly believes that having ...more

Susan Friesen, founder of the award-winning web development and digital marketing firm eVision Media...more

Author of four books and two screenplays; frequent magazine contributor. I have four other books "in...more

Rev Bresciani is the author of two Christian books. One book is an important and concisely written b...more

HomeLinksAbout UsContact UsTerms of UsePrivacy PolicyFAQResources
Copyright © 2020, All rights reserved.
Some pages may contain portions of text relating to certain topics obtained from under the GNU FDL license